Callodine Capital Management LP Purchases 182,837 Shares of Sanofi $SNY

Callodine Capital Management LP grew its stake in Sanofi (NASDAQ:SNY) by 35.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 698,046 shares of the company’s stock after acquiring an additional 182,837 shares during the period. Sanofi accounts for approximately 2.9% of Callodine Capital Management LP’s holdings, making the stock its 11th largest position. Callodine Capital Management LP’s holdings in Sanofi were worth $32,948,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Brighton Jones LLC increased its holdings in shares of Sanofi by 52.6% during the 4th quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock worth $261,000 after acquiring an additional 1,869 shares during the last quarter. AQR Capital Management LLC lifted its holdings in Sanofi by 107.2% during the 1st quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock valued at $1,693,000 after purchasing an additional 15,791 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Sanofi by 1.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock worth $2,732,000 after purchasing an additional 752 shares during the period. Sivia Capital Partners LLC boosted its position in Sanofi by 5.4% during the second quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock worth $326,000 after purchasing an additional 347 shares during the period. Finally, Savant Capital LLC increased its holdings in shares of Sanofi by 17.1% in the second quarter. Savant Capital LLC now owns 8,423 shares of the company’s stock valued at $407,000 after purchasing an additional 1,227 shares during the last quarter. Institutional investors and hedge funds own 14.03% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on SNY. UBS Group reiterated a “neutral” rating on shares of Sanofi in a research report on Friday, January 16th. Weiss Ratings restated a “hold (c)” rating on shares of Sanofi in a research note on Monday, December 29th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Sanofi in a research report on Friday, January 16th. Guggenheim cut shares of Sanofi from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 9th. Finally, TD Cowen reissued a “hold” rating on shares of Sanofi in a report on Tuesday, December 30th. Five research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, Sanofi currently has an average rating of “Hold” and an average target price of $62.67.

Sanofi Price Performance

Shares of SNY opened at $43.60 on Friday. The stock has a market cap of $106.34 billion, a PE ratio of 12.11, a PEG ratio of 1.13 and a beta of 0.45. The company has a quick ratio of 0.73, a current ratio of 1.09 and a debt-to-equity ratio of 0.20. The business has a 50-day simple moving average of $46.85 and a two-hundred day simple moving average of $48.24. Sanofi has a 12-month low of $43.34 and a 12-month high of $59.17.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.